Medegen continues to believe that ICU’s valve product, CLC-2000, infringes on the company’s patent for its proprietary valve technology. This patent covers a number of Medegen’s novel inventions in luer-activated valves, including the use of positive displacement technology, which reduces the occurrence of common vascular access device-related complications.
Jeffrey Goble, president of Medegen, said: “Medegen’s intellectual property is valuable and we feel strongly about protecting our innovations and are confident we will prevail in the appeal process.”